|
1
|
Mishra SK, Millman SE and Zhang L:
Metabolism in acute myeloid leukemia: Mechanistic insights and
therapeutic targets. Blood. 141:1119–1135. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Russell JA, Irish W, Balogh A, Chaudhry
MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB,
et al: The addition of 400 cGY total body irradiation to a regimen
incorporating once-daily intravenous busulfan, fludarabine, and
antithymocyte globulin reduces relapse without affecting nonrelapse
mortality in acute myelogenous leukemia. Biol Blood Marrow
Transplant. 16:509–514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khoury JD, Solary E, Abla O, Akkari Y,
Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et
al: The 5th edition of the World Health Organization classification
of haematolymphoid tumours: Myeloid and histiocytic/dendritic
neoplasms. Leukemia. 36:1703–1719. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Termuhlen AM, Klopfenstein K, Olshefski R,
Rosselet R, Yeager ND, Soni S and Gross TG: Mobilization of
PML-RARA negative blood stem cells and salvage with autologous
peripheral blood stem cell transplantation in children with
relapsed acute promyelocytic leukemia. Pediatr Blood Cancer.
51:521–524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Monzen S, Yoshino H, Kasai-Eguchi K and
Kashiwakura I: Characteristics of myeloid differentiation and
maturation pathway derived from human hematopoietic stem cells
exposed to different linear energy transfer radiation types. PLoS
One. 8:e593852013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanda Y, Izutsu K, Hirai H, Sakamaki H,
Iseki T, Kodera Y, Okamoto S, Mitsui H, Iwato K, Hirabayashi N, et
al: Effect of graft-versus-host disease on the outcome of bone
marrow transplantation from an HLA-identical sibling donor using
GVHD prophylaxis with cyclosporine A and methotrexate. Leukemia.
18:1013–1019. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong JYC, Filippi AR, Dabaja BS, Yahalom J
and Specht L: Total body irradiation: Guidelines from the
international lymphoma radiation oncology group (ILROG). Int J
Radiat Oncol Biol Phys. 101:521–529. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alfonso JCL and Berk L: Modeling the
effect of intratumoral heterogeneity of radiosensitivity on tumor
response over the course of fractionated radiation therapy. Radiat
Oncol. 14:882019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hazawa M, Hosokawa Y, Monzen S, Yoshino H
and Kashiwakura I: Regulation of DNA damage response and cell cycle
in radiation-resistant HL60 myeloid leukemia cells. Oncol Rep.
28:55–61. 2012.PubMed/NCBI
|
|
10
|
Monzen S, Takimura K, Kashiwakura I and
Hosokawa Y: Acute promyelocytic leukemia mutated to radioresistance
suppressed monocyte lineage differentiation by phorbol 12-myristate
13-acetate. Leuk Res. 37:1162–1169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Monzen S, Chiba M and Hosokawa Y: Genetic
network profiles associated with established resistance to ionizing
radiation in acute promyelocytic leukemia cells and their
extracellular vesicles. Oncol Rep. 35:749–756. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Monzen S, Chiba M, Ueno T, Morino Y,
Terada K, Yamaya H and Hosokawa Y: A radioresistant fraction of
acute promyelocytic leukemia cells exhibit CD38 cell-surface
antigen and mRNA expression. Oncol Lett. 15:6709–6714.
2018.PubMed/NCBI
|
|
13
|
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS,
Wu W, Zhang FQ, Chen Y, Zhou L, et al: Studies on treatment of
acute promyelocytic leukemia with arsenic trioxide: remission
induction, follow-up, and molecular monitoring in 11 newly
diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Blood. 94:3315–3324. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soignet SL, Frankel SR, Douer D, Tallman
MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA,
Steinherz P, et al: United States multicenter study of arsenic
trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol.
19:3852–3860. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shigeno K, Naito K, Sahara N, Kobayashi M,
Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R and Ohnishi
K: Arsenic trioxide therapy in relapsed or refractory Japanese
patients with acute promyelocytic leukemia: Updated outcomes of the
phase II study and postremission therapies. Int J Hematol.
82:224–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou P, Kalakonda N and Comenzo RL:
Changes in gene expression profiles of multiple myeloma cells
induced by arsenic trioxide (ATO): Possible mechanisms to explain
ATO resistance in vivo. Br J Haematol. 128:636–644. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ho SY, Wu WJ, Chiu HW, Chen YA, Ho YS, Guo
HR and Wang YJ: Arsenic trioxide and radiation enhance apoptotic
effects in HL-60 cells through increased ROS generation and
regulation of JNK and p38 MAPK signaling pathways. Chem Biol
Interact. 193:162–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yousefnia S: Mechanistic effects of
arsenic trioxide on acute promyelocytic leukemia and other types of
leukemias. Cell Biol Int. 45:1148–1157. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matt S and Hofmann TG: The DNA
damage-induced cell death response: A roadmap to kill cancer cells.
Cell Mol Life Sci. 73:2829–2850. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Faramarzian Azimi Maragheh B, Fatourachi
P, Mohammadi SM, Valipour B, Behtari M, Dehnad A and Nozad
Charoudeh H: Streptomyces Levis ABRIINW111 inhibits SW480
cells growth by apoptosis induction. Adv Pharm Bull. 8:675–682.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheung EC and Vousden KH: The role of ROS
in tumour development and progression. Nat Rev Cancer. 22:280–297.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bai X, Ni J, Beretov J, Wasinger VC, Wang
S, Zhu Y, Graham P and Li Y: Activation of the eIF2α/ATF4 axis
drives triple-negative breast cancer radioresistance by promoting
glutathione biosynthesis. Redox Biol. 43:1019932021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ning S, Zhang T, Lyu M, Lam JWY, Zhu D,
Huang Q and Tang BZ: A type I AIE photosensitiser-loaded biomimetic
nanosystem allowing precise depletion of cancer stem cells and
prevention of cancer recurrence after radiotherapy. Biomaterials.
295:1220342023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jambrovics K, Uray IP, Keillor JW, Fésüs L
and Balajthy Z: Benefits of combined all-trans retinoic acid and
arsenic trioxide treatment of acute promyelocytic leukemia cells
and further enhancement by inhibition of atypically expressed
transglutaminase 2. Cancers (Basel). 12:6482020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jambrovics K, Botó P, Pap A, Sarang Z,
Kolostyák Z, Czimmerer Z, Szatmari I, Fésüs L, Uray IP and Balajthy
Z: Transglutaminase 2 associated with PI3K and PTEN in a
membrane-bound signalosome platform blunts cell death. Cell Death
Dis. 14:2172023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu J, Koken MH, Quignon F, Chelbi-Alix
MK, Degos L, Wang ZY, Chen Z and de Thé H: Arsenic-induced PML
targeting onto nuclear bodies: implications for the treatment of
acute promyelocytic leukemia. Proc Natl Acad Sci USA. 94:3978–3983.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jing Y, Dai J, Chalmers-Redman RM, Tatton
WG and Waxman S: Arsenic trioxide selectively induces acute
promyelocytic leukemia cell apoptosis via a hydrogen
peroxide-dependent pathway. Blood. 94:2102–2111. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Davison K, Côté S, Mader S and Miller WH:
Glutathione depletion overcomes resistance to arsenic trioxide in
arsenic-resistant cell lines. Leukemia. 17:931–940. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sumi D, Shinkai Y and Kumagai Y: Signal
transduction pathways and transcription factors triggered by
arsenic trioxide in leukemia cells Toxicol Appl Pharmacol.
244:385–392. 2010.PubMed/NCBI
|
|
30
|
Li J: Downregulation of ROS1 enhances the
therapeutic efficacy of arsenic trioxide in acute myeloid leukemia
cell lines. Oncol Lett. 15:9392–9396. 2018.PubMed/NCBI
|
|
31
|
Heinke L: Mitochondrial ROS drive cell
cycle progression. Nat Rev Mol Cell Biol. 23:5812022. View Article : Google Scholar : PubMed/NCBI
|
